These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38270832)

  • 21. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
    Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
    J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASO Author Reflections: Significance of Skeletal Muscle Loss After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Xiao X; Fang PH; Zhou JF; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3854-3855. PubMed ID: 38265614
    [No Abstract]   [Full Text] [Related]  

  • 23. ASO Author Reflections: Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer.
    Ohkura Y
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):703-704. PubMed ID: 30251022
    [No Abstract]   [Full Text] [Related]  

  • 24. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
    von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
    Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study.
    Shimoji H; Karimata H; Nagahama M; Nishimaki T
    World J Surg; 2013 Sep; 37(9):2180-8. PubMed ID: 23649529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
    Park J; Yea JW; Oh SA; Park JW
    Radiat Oncol; 2021 Nov; 16(1):219. PubMed ID: 34775988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.
    Bosch DJ; Wang D; Nijsten MW; Mul VE; Hospers GA; Burgerhof JG; Struys MM; Plukker JT
    Am J Surg; 2016 Jul; 212(1):89-95. PubMed ID: 27036621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASO Author Reflections: A Novel, Sensitive, and Effective Index in Predicting Therapeutic Response of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Ann Surg Oncol; 2024 Jan; 31(1):241-242. PubMed ID: 37838649
    [No Abstract]   [Full Text] [Related]  

  • 31. Radiation With Neoadjuvant Chemotherapy Does Not Improve Outcomes in Esophageal Squamous Cell Cancer.
    Miller JA; Groman A; Yendamuri S; Hennon M
    J Surg Res; 2019 Apr; 236():259-265. PubMed ID: 30694764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia.
    Kuo YH; Chien YW; Chen PR; Feng CL; Li CC; Chien CR
    World J Surg Oncol; 2019 Dec; 17(1):222. PubMed ID: 31856840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant Therapy for Patients with a Tumor-Positive Resection Margin After Neoadjuvant Chemoradiotherapy and Esophagectomy.
    van der Zijden CJ; van der Sluis PC; Mostert B; Nuyttens JJME; Spaander VMCW; Valkema R; Ruurda JP; Wijnhoven BPL; Lagarde SM
    Ann Surg Oncol; 2024 Jun; 31(6):3813-3818. PubMed ID: 38245648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Outcome of Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer with Clinical Complete Response to Neoadjuvant Therapy.
    Ohkura Y; Shindoh J; Ueno M; Iizuka T; Udagawa H
    Ann Surg Oncol; 2018 Aug; 25(8):2428-2433. PubMed ID: 29564587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.